A Novel ‘Radiotherapy from Within’ Platform Technology for the Targeted Treatment of Solid Tumours Called ‘BAT-90’

BetaGlue is developing an innovative ""radiotherapy from within"", personalized and cost-effective anti-tumoural platform technology called BAT-90.

BAT-90 maximises the therapeutic index of loco-regional treatment by eliminating off-target radiation dose in a simple and easy to use product.

The product aims to provide a radiotherapeutic treatment option for a range of solid tumour types including: unresectable hepatocellular carcinoma (HCC) and locally advanced and borderline resectable pancreatic cancer (PDAC) patients, where in the first-line setting, there exists a major unmet clinical need.

Through the percutaneous administration of BAT-90 under radiological guidance (usually ultrasound) BAT-90 overcomes the accessibility and off-target side effect limitations of external beam radiotherapy, forms of brachytherapy, proton beam radiotherapy trans-arterial radio-embolisation and microwave ablation.

BAT-90 has already demonstrated safety and preliminary effectiveness in first-in-human clinical studies.